The treatment, Dupixent, was approved May 20 to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds.
Dupixent is a monoclonal antibody that helps stop part of the inflammatory pathway of the esophagus in those with the disease, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
